Return-Path: <docteur.laurentmasson@gmail.com>
Received: from mwinf5c21 (mwinf5c21 [10.223.111.71])
	 by mwinb0j06 with LMTPA;
	 Sun, 18 Mar 2012 16:39:27 +0100
X-Sieve: CMU Sieve 2.3
Received: from mail-iy0-f181.google.com ([209.85.210.181])
	by mwinf5c21 with ME
	id n3fS1i0363vNWAR013fSPr; Sun, 18 Mar 2012 16:39:27 +0100
X-bcc: biolo.laurent.masson@orange.fr
X-ME-bounce-domain: orange.fr
X-ME-engine: default
X-me-spamrating: 40.00
X-me-spamcause: (0)(0000)gggruggvucftvghtrhhoucdtuddrfeegvddrgeeggdefkecuteggodetufcurfhrohhfihhlvgemucfogfenuceurghilhhouhhtmecugedttdenucenucfhrhhomhepnfgruhhrvghnthcuofgrshhsohhnuceoughotghtvghurhdrlhgruhhrvghnthhmrghsshhonhesghhmrghilhdrtghomheqnecujfgurhepfffkuffhvfgtsegrtderredttddu
X-me-spamlevel: not-spam
X-ME-Entity: ofr
Received: by iaoo28 with SMTP id o28so9349134iao.26
        for <biolo.laurent.masson@orange.fr>; Sun, 18 Mar 2012 08:39:26 -0700 (PDT)
DKIM-Signature: v=1; a=rsa-sha256; c=relaxed/relaxed;
        d=gmail.com; s=20120113;
        h=mime-version:date:message-id:subject:from:to:content-type;
        bh=91dzwiT02HB6cDFkV3wmUpsk6AYER5WY5aRvs5koHE0=;
        b=Rs6nLqltHD4TK1YhiZ4mM3NNogpdzqpf5j7ohJIjtU1emv3ZqpyHHXywfZAlx7HhGG
         5LR5PX/Gcmash0hs8IddyLJSnt65s6OKrmrSUzyUXLSiv8flJZvDQ8KaWOo2+kTIQi9f
         OMe42Wo+33eDgNKOYgXZAzZsuzMO1vUxLk48oDgw2lB6eUKbtujGLkvnGtcOsQXABIZB
         5xpNdnelQ2Dn9E3BuhL2It/529wYVYeFZ4aFe/Ib8HrVAaFJMWr38+FrQIaEgCf8l2IT
         1JrB057kd4OidyriSGe5MiV7WucQVJvEaYmGA5IUUb8HpCCgfpZzw0FWWQK7B4fWIRc6
         oVGA==
MIME-Version: 1.0
Received: by 10.50.41.161 with SMTP id g1mr4079074igl.5.1332085166411; Sun, 18
 Mar 2012 08:39:26 -0700 (PDT)
Received: by 10.42.73.4 with HTTP; Sun, 18 Mar 2012 08:39:26 -0700 (PDT)
Date: Sun, 18 Mar 2012 16:39:26 +0100
Message-ID: <CAFQawyKkFbdwKYWpA9CSfxKFPRJPumWKQAVrcB9cN_H6vY+NAQ@mail.gmail.com>
Subject: test biolo
From: Laurent Masson <docteur.laurentmasson@gmail.com>
To: biolo.laurent.masson@orange.fr
Content-Type: multipart/alternative;
  boundary=14dae93408d927915a04bb863f5c
Status: R
X-Status: N
X-KMail-EncryptionState:  
X-KMail-SignatureState:  
X-KMail-MDN-Sent:  

--14dae93408d927915a04bb863f5c
Content-Type: text/plain; charset=ISO-8859-1
Content-Transfer-Encoding: quoted-printable

B2030800528
CONDAT
MONIQUE
42 IMPASSE DES CHARMILLES

74370 ARGONAY
14/04/1934
2340475062005 34
12031760024
17/03/2012
.          labo.nicolas
MASSL      laurent.masson
                LABORATOIRE D'ANALYSES DE BIOLOGIE MEDICALE
                            Laboratoire NICOLAS
                              2, rue Oberkampf

                            78350 JOUY EN JOSAS
                            num=E9ro: 78 3 70816 7
Prescrit par DR MASSON LAURENT 78350 JOUY EN JOSAS copie au

     Dossier : 17/03/12-6-0024                    DR MASSON LAURENT
     Enregistr=E9 le 17/03/12 08H50                 xx ADRESSE
     Edit=E9 et diffus=E9 le 17/03/12 =E0 12H34
     Examens effectu=E9s par le laboratoire         99999 NOWHERE

Compte rendu d'=E9dition R=E9=E9dition d'analyses de biologie m=E9dicale
Madame TRUC MUCH, (NJF) BIDULLE
42 RUE DE MACHIN 99999 NOWHERE N=B0 secu : 2 99 99 99 999 999  99
Date de naissance : 14/04/1934 77 Ans


COAGULATION
                                                  valeurs de r=E9f=E9rence
Ant=E9riorit=E9s
 TAUX DE PROTHROMBINE

15/03/12
   Nom du m=E9dicament ..........  Coumadine 2 mg                   Coumadi=
ne
2 mg
   Posologie ..................  1.25 mg/j                        1/2
comprim=E9 par jour

   T.P. t=E9moin ................
   T.P. patient ...............
   Taux de prothrombine ....... *46        %          70 =E0 100
43
   Technique chronom=E9trique - TP Fibrinogen recombiplastine - ACL TOP - I=
L
   I.N.R. ..................... 1,93
1,98
   Technique chronom=E9trique - TP Fibrinogen recombiplastine - ACL TOP - I=
L



 ZONES THERAPEUTIQUES            INR

 - Pr=E9vention et traitement des Thromboses veineuses, Embolies syst=E9miq=
ues
et pulmonaires: 2,0 < INR < 3,0
 - Proth=E8ses valvulaires:
 - Embolies syst=E9miques r=E9cidivantes:  3,0 < INR < 4,0
                                 3,5 < INR < 4,5



   /CR/00003/PDF/NORMAL//func.HISTORES.png




Examens Techniques


****LAB****
RES|Nom du m=E9dicament|INRME|C|Coumadine 2 mg|||||C
RES|Posologie|INRPO|A|1.25 mg/j|||||C
RES|Taux de prothrombine|TP|N|46|%|70|100|L|C
RES|I.N.R.|INR|N|1.93||||N|C
RES|Tri RSA 05|RSA05|A|TRI|||||C
****FIN****
****FINFICHIER****

--14dae93408d927915a04bb863f5c
Content-Type: text/html; charset=ISO-8859-1
Content-Transfer-Encoding: base64
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--14dae93408d927915a04bb863f5c--
